11/6
01:02 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
11/6
09:00 am
edit
Editas Medicine to Participate in Upcoming Investor Conferences
Low
Report
Editas Medicine to Participate in Upcoming Investor Conferences
11/6
07:21 am
edit
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
Medium
Report
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
11/5
05:34 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/5
01:04 pm
edit
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]
Low
Report
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]
11/5
11:36 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.
11/5
11:19 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.
11/5
10:41 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $9.00 to $7.00. They now have an "overweight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $9.00 to $7.00. They now have an "overweight" rating on the stock.
11/5
10:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Truist Financial Co. from $12.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Truist Financial Co. from $12.00 to $8.00. They now have a "buy" rating on the stock.
11/5
09:43 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "equal weight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $7.00 to $5.00. They now have an "equal weight" rating on the stock.
11/4
01:15 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
11/4
07:30 am
edit
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Low
Report
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
10/23
11:42 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $3.00. They now have an "in-line" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $3.00. They now have an "in-line" rating on the stock.
10/23
10:46 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $27.00 to $9.00. They now have an "overweight" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Wells Fargo & Company from $27.00 to $9.00. They now have an "overweight" rating on the stock.
10/22
06:46 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Chardan Capital from $20.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Chardan Capital from $20.00 to $12.00. They now have a "buy" rating on the stock.
10/22
11:59 am
edit
EDIT Editas_Medicine_Strategic_Update_-_October_2024_-_FINAL [Seeking Alpha]
Low
Report
EDIT Editas_Medicine_Strategic_Update_-_October_2024_-_FINAL [Seeking Alpha]
10/22
11:49 am
edit
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript [Seeking Alpha]
Low
Report
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript [Seeking Alpha]
10/22
07:00 am
edit
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
High
Report
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
10/21
04:30 pm
edit
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
High
Report
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
10/18
04:06 pm
edit
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept [Yahoo! Finance]
High
Report
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept [Yahoo! Finance]
10/18
04:01 pm
edit
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
High
Report
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
10/12
09:46 am
edit
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company [Yahoo! Finance]
Low
Report
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company [Yahoo! Finance]
10/4
12:48 am
edit
Editas Medicine gets over $50M financing with DRI Healthcare Trust Oct. 04, 2024 12:45 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
Low
Report
Editas Medicine gets over $50M financing with DRI Healthcare Trust Oct. 04, 2024 12:45 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
10/3
06:11 pm
edit
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust [Yahoo! Finance]
Medium
Report
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust [Yahoo! Finance]
10/3
06:00 pm
edit
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Medium
Report
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust